Why is H Lundbeck stock rallying today?

H Lundbeck B stock is experiencing a 2.6% rally, trading at DKK 43.66, following UBS's upgrade from Neutral to Buy and raising its price target to DKK 52 from DKK 45. This positive shift stems from the transformative commercial potential of bexicaserin, the company's investigational treatment for developmental and epileptic encephalopathies (DEEs).

UBS projects bexicaserin sales to exceed market expectations by roughly 30%, potentially offsetting the anticipated Rexulti patent cliff in 2029 and alleviating recent concerns weighing on the shares. A pivotal factor in UBS's thesis is the accelerated timeline: Lundbeck advanced the Phase 3 DEEp OCEAN trial readout in DEEs from 2027 to the end of 2026, announced during the Q3 2026 results.

Additionally, the September 15 completion of randomization in the companion DEEp SEA trial for Dravet syndrome signifies fully enrolled pivotal bexicaserin trials. This development improves investor visibility on the asset. The B-share, affected by a structural overhang from the voluntary A-to-B share exchange offer that expired on September 16, 2026, is now freer to re-rate based on underlying fundamentals.

Furthermore, global equity markets are supportive, with U.S. indices rising and a risk-on tone benefiting growth-oriented pharmaceutical names. Together, these factors—high-conviction analyst upgrade, de-risked pipeline schedule, B-share dilution relief, and a favorable macro environment—have enabled the stock to recover toward its recent trading range peak.